Publications by authors named "Carol Connell"

Claim this Profile
R
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Christina Charles-Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R Ytterberg, Carol A Connell

Arthritis Rheumatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Performance of a Nutrition Knowledge Questionnaire With a Low Socioeconomic Status Population Using Rasch Analysis.
Holly F Huye, Peter Paprzycki, Carol L Connell

Health Promot Pract· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Carol A Connell

RMD Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a analysis of ORAL Surveillance.
George A Karpouzas, Zoltán Szekanecz, Eva Baecklund, Ted R Mikuls, Deepak L Bhatt, Carol A Connell

Ther Adv Musculoskelet Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, Jon T Giles, Steven R Ytterberg, Carol A Connell

Ann Rheum Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Jeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L Bhatt, Levent M Gunay, Carol A Connell

Ann Rheum Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, Deepak L Bhatt, Jon T Giles, Carol A Connell

Ann Rheum Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
Karen E Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A Connell

Ther Adv Musculoskelet Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell

Ann Rheum Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Xiaoxing Wang, Martin E Dowty, Ann Wouters, Svitlana Tatulych, Carol A Connell

Eur J Drug Metab Pharmacokinet· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply.
Steven R Ytterberg, Deepak L Bhatt, Carol A Connell

N Engl J Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Steven R Ytterberg, Deepak L Bhatt, Ted R Mikuls, Gary G Koch, Roy Fleischmann, Carol A Connell

N Engl J Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
Joel M Kremer, Clifton O Bingham, Laura C Cappelli, Jeffrey D Greenberg, Ann M Madsen, Carol A Connell

ACR Open Rheumatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Kevin L Winthrop, Gustavo Citera, David Gold, Dan Henrohn, Carol A Connell

Ann Rheum Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serious infection with tofacitinib in patients with rheumatoid arthritis: the importance of context.
Jose L Rivas, Thomas Jones, Carol A Connell

Lancet Rheumatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Impact of a Preschool Obesity Prevention Intervention Enhanced With Positive Behavioral Supports for Mississippi Head Start Centers.
Holly F Huye, Carol L Connell, Brad A Dufrene, Richard S Mohn, Caroline Newkirk

J Nutr Educ Behav· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Philip Mease, Christina Charles-Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Carol Connell

Ann Rheum Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Vibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, Edward Keystone, Joel Kremer, Carol A Connell

Clin Exp Rheumatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Paul Bird, Stephen Hall, Peter Nash, Carol A Connell, Kenneth Kwok

RMD Open· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to Healthcare Seeking and Provision Among African American Adults in the Rural Mississippi Delta Region: Community and Provider Perspectives.
Carol L Connell, Sherry C Wang, LaShaundrea Crook, Kathy Yadrick

J Community Health· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
Désirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, Edward Keystone, Joel Kremer, Carol A Connell

Arthritis Rheumatol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expenditure, Coping, and Academic Behaviors among Food-Insecure College Students at 10 Higher Education Institutes in the Appalachian and Southeastern Regions.
Rebecca L Hagedorn, Laura H McArthur, Lanae B Hood, Maureen Berner, Elizabeth T Anderson Steeves, Carol L Connell

Curr Dev Nutr· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maternity Nurses' Knowledge and Practice of Breastfeeding in Mississippi.
Amir Alakaam, Jennifer Lemacks, Kathleen Yadrick, Carol Connell, Hwanseok Winston Choi

MCN Am J Matern Child Nurs· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
Vibeke Strand, Arthur Kavanaugh, Alan J Kivitz, Désirée van der Heijde, Kenneth Kwok, Carol Connell

Rheumatol Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Alan J Kivitz, Stanley Cohen, Edward Keystone, Ronald F van Vollenhoven, Boulos Haraoui, Carol A Connell

Semin Arthritis Rheum· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis